Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2026--

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making effective, affordable GLP-1s accessible to Canadians for whom cost has long been a barrier to treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520249611/en/

Nearly two-thirds of Canadian adults are overweight or living with obesity, but cost has remained a significant barrier to access the treatment they need. As the market becomes more dynamic and prices fall across the GLP-1 landscape, more eligible patients are now able to find the treatment that works best for their lifestyle and budget. This launch reflects Hims & Hers' ability to rapidly identify opportunities to help customers in global markets access safe, affordable care.

"Bringing generic semaglutide to Canada is a meaningful milestone, but it's also a signal of something larger: our conviction that the model we've built in the United States can and should serve customers around the world," said Mike Chi, Chief Operating Officer, Hims & Hers. "There are millions of people in markets around the world who are ready for more ways to find affordable, high-quality care. Our ability to enter a new market, build a locally credible program, deliver access to first-of-its-kind medical treatment, and generate real impact at scale is what sets us apart."

"Generics have always played a critical role in expanding access to medicines that change lives,” said Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada. “Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient. Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford."

Now through Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include generic semaglutide or branded options, alongside unlimited and ongoing Care Team access and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting habits for long-term weight management. All Canadian customers are seen by Canadian providers who bring local clinical expertise and a deep understanding of the Canadian healthcare landscape.

Generic semaglutide is authorized for sale by Health Canada for the management of Type 2 diabetes. It may be prescribed off-label for weight management in a licensed healthcare provider's sole clinical judgment. Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ ability to expand internationally and serve customers around the globe, and any assumptions relating to the foregoing. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to our ability to successfully expand into new markets or specialties; our ability to launch new products or offerings on expected timelines or at all; expectations regarding market acceptance, user experience and customer retention; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of May 20, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release.

By introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts

MINNEAPOLIS (AP) — A judge on Thursday handed down an extraordinary prison sentence — nearly 42 years — to the former leader of a Minnesota nonprofit who was convicted in a staggering $250 million fraud case that helped ignite an immigration crackdown by the Trump administration.

Aimee Bock ran Feeding Our Future, which had claimed it helped provide millions of meals to children in need during the pandemic.

“I understand I failed. I failed the public, my family, everyone,” Bock said in federal court.

President Donald Trump used the fraud cases against Bock and many others to initially justify a massive surge of federal officers to the Minneapolis-St. Paul area last winter, leading to a pushback by residents and the deaths of two people.

“Feeding Our Future operated like a cash pipeline, open to anyone willing to submit fraudulent claims and pay kickbacks,” prosecutors said in a court filing. “The ripple effects of her actions are profound, immeasurable, and will have lasting consequences for both Minnesota and the nation.”

Bock was convicted last year of multiple counts involving conspiracy, wire fraud and bribery. She had long insisted she was innocent.

Her lawyer, Kenneth Udoibok, argued for a much shorter sentence, saying Bock had provided information to investigators. He argued that Bock had been unfairly painted as the mastermind and insisted that two co-defendants were responsible for running the scams.

The nonprofit sat atop a fraud network that included a web of partner organizations, phony distribution sites, kickbacks and fake lists of children supposedly being fed, prosecutors say. Dozens of people, many from the state’s large Somali community, have been convicted for their roles in a series of overlapping food fraud cases that have spent years in the courts.

Meanwhile, authorities this week filed additional charges against others in a sprawling investigation into federal social service spending in Minnesota.

The targets include Fahima Mahamud, who was CEO of Future Leaders Early Learning Center, a childcare center in Minneapolis. Over three years, Mahamud’s organization was reimbursed approximately $4.6 million for services on behalf of people who didn’t make a required copayment, prosecutors allege.

A message seeking comment from her lawyer was not immediately returned Thursday. Mahamud was charged separately in February with fraud related to meals. She has pleaded not guilty.

Two other people were charged with conspiring to get $975,000 in Medicaid subsidies for housing services that were not provided. They’re expected to plead guilty in June, according to a court filing.

Two additional people were accused of receiving $21.1 million by billing Medicaid for autism therapy that was either unnecessary or not provided. Investigators said they paid families as much as $1,500 per child per month to add their names to the program and get reimbursement.

Trump, who has long derided Somalis, last year blasted the state as “a hub of fraudulent money laundering activity.” He also criticized the leadership of Gov. Tim Walz, the Democrats’ vice presidential nominee in the 2024 election.

“Somali gangs are terrorizing the people of that great State, and BILLIONS of Dollars are missing. Send them back to where they came from,” Trump wrote on social media.

Bock is white and the U.S. Attorney’s Office says the overwhelming majority of defendants in the cases are of Somali descent. Most are U.S. citizens.

The immigration surge led to repeated protests and confrontations between residents and federal officers and resulted in the killings of Renee Good and Alex Pretti.

FILE - Aimee Bock, founder and executive director of the nonprofit organization Feeding Our Future, arrives at the Minneapolis federal courthouse with her attorney, Ken Udoibok, right, on March 19, 2025, in Minneapolis. (Kerem Yücel/Minnesota Public Radio via AP, File)